whitepaper
Whitepaper: Mitochondrial toxicity assessment
This whitepaper establishes a customised XF assay solution for the detection of mitochondrial toxicity using standardised parameters.
List view / Grid view
Screening
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
whitepaper
Application note: Agilent XF real time ATP rate assay
Discover how the Agilent Seahorse XF Real Time ATP rate assay provides a simple robust workflow that can identify metabolic targets for drug discovery
whitepaper
Whitepaper: Organoids: How close are we to the clinic?
Explore current insights into the clinical possibilities posed by organoids and delve into short and long-term prospects for therapeutic screening and personalised regenerative medicine in this whitepaper.
whitepaper
Whitepaper: Oncology therapeutics discovery solutions
Streamline oncology therapeutic development with CST® recombinant monoclonal antibodies, ELISA & cellular assay kits, & custom products & services.
webinar
Using integrative biophysical approaches to understand GPCR regulation by β-arrestins
30 January 2023 | By Thermo Fisher Scientific
Watch this webinar to learn how an integrated structural biology workflow can be used to get crucial structural insights on key protein targets that are of therapeutic interest.
article
Artificial intelligence: a great crash of hype into reality
Technology is infamous for falling into a hype cycle, with its peaks and valleys of exaggerated expectations and disillusionment — AI-driven drug discovery is no exception. In this article, Aaron Daugherty, Vice President Discovery at Aria Pharmaceuticals, highlights how the industry can use AI to transform research.
whitepaper
Whitepaper: Neurodegeneration therapeutics discovery
Advance your neurodegeneration research with our broad antibody portfolio, ready-to-use ELISA, and cellular kits to develop new efficacious therapies.
news
Study suggests existing cancer drug may be effective against non-alcoholic fatty liver disease
The researchers used single-nuclear sequencing and advanced three-dimensional glass imaging of mice to find new drug targets for non-alcoholic fatty liver disease.
whitepaper
Glossary: Multiplexing 101 – The essential guide
What is multiplexed immunofluorescence microscopy imaging?
whitepaper
Poster: Antibodies for microglial activation states
Development of novel rabbit monoclonal antibodies to characterise microglial activation states in murine models of Alzheimer’s disease.
whitepaper
Poster: Tumour-infiltrating immune cell markers
Need some direction in choosing immune cell markers? Whether you are working with human cells or a mouse model, CST has you covered!
webinar
Validated bioassays for metabolic & gastrointestinal diseases: Accelerating development of GLP-1 & -2 therapeutics
20 December 2022 | By Eurofins DiscoverX Corp.
In this webinar, we present an approach for building MOA-based, simple, ready-to-use GLP-1 and GLP-2 bioassays and discuss assay validation results from Eurofins BPT.
video
Webinar: Neuroinflammation discovery assays
Join Malvern Panalytical for a 15-minute webinar to learn about ex vivo inflammasome slice assays for neuroinflammation discovery.
article
How many drug discovery breakthroughs have we missed?
Today’s drug screening methods use one or two types of data. However, disease biology is not replicable by simple screening models because diseases are complex and heterogenous. However, advanced screening methods that process dozens of data sources at one time have uncovered novel hits that have been overlooked across the…
whitepaper
Article: Understanding potency in cell and gene therapy development
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
